Chemoradiotherapy is named as an intervention in 5 current clinical trials in our China register. 4 are recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Suzhou Municipal Hospital (1). The most-studied condition is Cervical Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
NCT05397769 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy
|
Phase 2 | Recruiting | Sun Yat-sen University | China |
|
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
NCT05872724 · ClinicalTrials.gov ↗ · Cervical Cancer
|
Phase 2 | Recruiting | Suzhou Municipal Hospital | China |
|
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT06059261 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
|
Phase 2 | Recruiting | Chongqing University Cancer Hospital | China |
|
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
NCT07448077 · ClinicalTrials.gov ↗ · Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
|
Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | China |
|
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
NCT07386704 · ClinicalTrials.gov ↗ · Pancreatic Cancer Non-resectable
|
Phase 2 | By invitation | Peking University First Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Suzhou Municipal Hospital | 1 |
| Chongqing University Cancer Hospital | 1 |
| Peking University First Hospital | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Sun Yat-sen University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name Chemoradiotherapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Suzhou Municipal Hospital (1), Chongqing University Cancer Hospital (1), Peking University First Hospital (1) and Hebei Medical University Fourth Hospital (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Chemoradiotherapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Chemoradiotherapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Chemoradiotherapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.